Loading...
XKRX
287410
Market cap647mUSD
Oct 18, Last price  
12,900.00KRW
Name

Jeisys Medical Inc

Chart & Performance

D1W1MN
XKRX:287410 chart
P/E
39.30
P/S
6.81
EPS
328.22
Div Yield, %
Shrs. gr., 5y
Rev. gr., 5y
%
Revenues
143.03b
+22.72%
47,828,639,03081,295,998,520116,549,559,690143,029,552,900
Net income
24.80b
-8.59%
7,542,562,69013,591,582,89027,129,757,07024,800,415,090
CFO
32.68b
+29.41%
53,084,63016,123,279,25020,300,992,09025,250,838,53032,677,912,970

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Jeisys Medical Inc. is a company dedicated to the innovation and production of medical equipment, catering to a range of healthcare professionals including plastic surgeons, dermatologists, and other clinicians. Operating from its headquarters in Seoul, South Korea, the firm serves both its domestic market and international clients. Its comprehensive product line addresses various aesthetic and dermatological concerns, offering solutions for skin revitalization, firming, pigment correction, fat reduction, acne treatment, tattoo removal, and the management of scars and stretch marks. These advanced systems are branded under names such as ULTRAcel Q+, Cellec V, LIPOcel, AcGen, TRI-BEAM Premium, Edge ONE, SmoothCool, and ULTRAcel. The company distributes its offerings through an extensive network of partners. Jeisys Medical Inc. was established in 2001.
IPO date
May 08, 2018
Employees
Domiciled in
KR
Incorporated in
KR

Valuation

Title
KRW in thousands, except ratios and share amounts
FYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT